Global Antidiabetic Combinations Market, By Drug Class (Thiazolidinedione and Sulfonylurea Combination, Thiazolidinedione and Biguanide Combination, Others), Route of Administration (Oral, Injections, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Antidiabetic Combinations Market Analysis and Size
The global antidiabetic combinations market is expected to witness significant growth during the forecast period. Increased cases of type 2 diabetes drives the oral antidiabetic drugs market. An increase in government initiatives and high patient awareness level are some of the influencing factors driving market growth. Many major market players are contributing a lot in drug discovery and development. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global antidiabetic combinations market in the forecast period 2022-2029. The expected CAGR of global antidiabetic combinations market is tend to be around 6.50% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Diabetes is a metabolic disease that causes high blood sugar levels resulting in deficiency of insulin in the body. Medications that are used for the treatment of diabetes called as antidiabetic drugs. Antidiabetic combinations are fixed doses of a combination consisting of two or more classes of antidiabetic agents of the different pharmacological action and significantly improve glycaemic control in patients with diabetes. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Antidiabetic Combinations Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Drug Class (Thiazolidinedione and Sulfonylurea Combination, Thiazolidinedione and Biguanide Combination, Others), Route of Administration (Oral, Injections, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Aurobindo Pharma (India), Torrent Pharmaceuticals Ltd (India) |
|
Market Opportunities |
|
Global Antidiabetic Combinations Market Dynamics
Drivers
- Rising Incidence of Diabetes
The adult diabetes population in 2021 was approximately 537 million, and this number will rise to 643 million in 2030. There are several factors such as obesity, unhealthy diet, and physical inactivity, because of which the rate of newly diagnosed cases of Type 1 and Type 2 diabetes is seen to increase. Thus, this boosts the market growth.
- Growing Demand of Fixed Combination Therapy
Monotherapy does not provide adequate glucose control in many patients, and several unacceptable side effects have been noticed in patients with a higher dosage of a single agent. In contrast, fixed-dose combination antidiabetic medications are helpful and appropriate treatment options in this kind of patient to maintain good glycemic control. It has been witnessed that combination drug therapy helps to keep the HbA1c value below 7% for a patient. It helps minimize the side effects associated with high-dose treatment of a single agent and provides additional clinical benefits.
Opportunities
- Increasing Demand for Retail Pharmacies
The rise in the number of open angle glaucoma therapeutics delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
- Increasing Demand for Metformin
Among all the other drugs, metformin is still the most prescribed oral antidiabetic medication globally with a prescription rate of 45–50% of all prescriptions and also taken by over 150 million people each year. There are some long-term positive experiences with the use of metformin which are strong evidence of clinical efficacy, safety, low cost, general availability, high adherence rate, and cost-effectiveness. Thus, it creates an opportunity for the market growth.
Restraints/Challenges
- Patent Expiration Encourages New Launches
The patent expiration of old companies can create better opportunities for the new market players. Adopting combination therapies is a significant factor contributing to the growth of the antidiabetic combinations market. Further, R&D fundings are an add-on to the market
- High Cost
The huge expenditure of the treatment methods surely hamper the market growth.
This global antidiabetic combinations market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global antidiabetic combinations market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Antidiabetic Combinations Market
The incidence of diabetes in people hospitalized with COVID-19 infection and the physicians' understanding that improved glycemic control might improve outcomes and reduce hospital stay in patients with COVID-19 have truly underlined the importance of the oral antidiabetic drugs market. People with diabetes tend to have a weaker immune system; in this regard, the COVID-19 complication exaggerates the condition, and the immune system gets weaker. Thus, COVID-19 surely increased the antidiabetic combinations market.
Global Antidiabetic Combinations Market Scope
The global antidiabetic combinations market is segmented on the basis of drug class, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Thiazolidinedione and Sulfonylurea Combination
- Thiazolidinedione and Biguanide Combination
- Others
Route of Administration
- Oral
- Injections
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Antidiabetic Combinations Market Regional Analysis/Insights
The global antidiabetic combinations market is analysed and market size insights and trends are provided by drug class, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global antidiabetic combinations market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the large expenditure on healthcare and high prevalence of diabetes.
Asia-Pacific dominates the market due to the rise in population and increase in government institutions and awareness for diabetes.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Antidiabetic Combinations Market Share Analysis
The global antidiabetic combinations market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global antidiabetic combinations market.
Key players operating in the global antidiabetic combinations market include:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hikma Pharmaceuticals PLC (U.K.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bristol Myers Squibb Company (U.S.)
- GSK Plc. (U.K.)
- Bayer AG (Germany)
- Aurobindo Pharma (India)
- Torrent Pharmaceuticals Ltd (India)
SKU-
